Surgery Partners, Inc. (SGRY) Stock Price & Analysis
Surgery Partners, Inc. (SGRY) rose 3.35% to USD 15.73 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
SGRY last closed at USD 15.22; the session ranged USD 15.46–16.6 on volume of 4,092,677 shares. Market capitalization is $2.06B, with a 52-week range of USD 11.41–24.1 (NMS). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 15.73 |
|---|---|
| Change | ▲ 3.35% (up) |
| Previous Close | USD 15.22 |
| Open | USD 15.64 |
| Day Range | USD 15.46 – 16.6 |
| 52-Week Range | USD 11.41 – 24.1 |
| Volume | 4,092,677 shares |
| Market Cap | $2.06B |
| Exchange | NMS |
Technical Analysis (SGRY)
Nexqual's technical model rates SGRY "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.66 (neutral) |
| vs SMA50 | Above (USD 14.97) |
| MACD | 0.14 (positive) |
Analyst Ratings (SGRY)
Wall Street analysts rate SGRY "Buy" based on 11 analysts, with a mean price target of USD 18.64 (range USD 14–24), per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 18.64 |
| High Target | USD 24 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 9 / 3 / 0 |
Earnings (SGRY)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD 0.07 |
| Revenue Estimate | $830.32M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.03 vs est -0.14 ▲ beat |
| 2025-12-31 | USD 0.12 vs est 0.3 ▼ miss |
| 2025-09-30 | USD 0.13 vs est 0.16 ▼ miss |
| 2025-06-30 | USD 0.17 vs est 0.14 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (SGRY)
| Total Revenue | $3.34B |
|---|---|
| Revenue Growth (YoY) | +4.50% |
| Gross Margin | +22.83% |
| Operating Margin | +10.37% |
| Profit Margin | -2.28% |
| ROE | +2.75% |
| Debt / Equity | 116.01 |
| Current Ratio | 1.86 |
| Total Cash | $182.30M |
| Total Debt | $4.04B |
| Free Cash Flow | $199.06M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (SGRY)
Nexqual rates Surgery Partners, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 23%, operating 10% |
| Balance Sheet | Mixed — $182M cash vs $4.04B debt |
| Cash Flow | Solid — FCF $199M, 6% margin |
| Efficiency | Weak — ROE 3%, ROA 3.7% |
Ownership (SGRY)
| Insider Ownership | +1.79% |
|---|---|
| Institutional Ownership | +123.30% |
| Shares Outstanding | 130.79M |
| Float | 54.13M |
| Short % of Float | +22.94% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (SGRY)
Surgery Partners, Inc. is led by J. Eric Evans (age 48), CEO & Director, per Nexqual as of July 25, 2026 at 03:08 UTC.
| CEO & Director | J. Eric Evans (age 48) |
|---|---|
| Executive VP & CFO | David T. Doherty (age 53) |
| Executive VP & Chief Strategy Officer | Marissa A. Brittenham (age 40) |
| President of American Group | W. Trent Webb (age 45) |
| Executive Vice President, COO & National Group President | Justin R. Oppenheimer (age 40) |
Major Backers & Investors (SGRY)
Notable institutional backers of Surgery Partners, Inc. include Bain Capital Investors Llc, Janus Henderson Group PLC, JANUS INVESTMENT FUND-Janus Henderson Contrarian Fund, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bain Capital Investors Llc | 38.19% |
| Janus Henderson Group PLC | 10.35% |
| JANUS INVESTMENT FUND-Janus Henderson Contrarian Fund | 9.92% |
| Pentwater Capital Management Lp | 9.68% |
| King Street Capital Management, LP | 7.82% |
| UBS Group AG | 7.79% |
| ClearBridge Investments, LLC | 3.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.5% |
| BlackRock | 5.74% |
| Dimensional Fund Advisors | 4.05% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
From Surgery Partners, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Federal and State Privacy and Security Requirements We are subject to the Medicare Patient and Program Protection Act of 1987, as amended by the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), including the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act"), which was enacted as part of The American Recovery and Reinvestment Act of 2009.
- Our Growth Strategies Our differentiated operating model employs a multifaceted strategy to grow revenue, earnings and cash flow.
Partnerships
- The HITECH Act strengthened the requirements of the HIPAA privacy and security regulations and significantly increased the penalties for violations by introducing a tiered penalty system, with penalties of up to $50,000 per violation with a maximum civil penalty of $1.5 million in a calendar year for violations of the same requirement.
- We generally do not enter into contracts with physicians who use our surgical facilities, other than partnership and operating agreements with physicians who own interests in our surgical facilities, agreements for anesthesiology services and medical director agreements.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIVN | LivaNova PLC | USD 78.19 | ▼ 0.1% |
| OPCH | Option Care Health, Inc. | USD 21.66 | ▲ 2.41% |
| EVH | Evolent Health, Inc | USD 4.22 | ▼ 24.24% |
| PRVA | Privia Health Group, Inc. | USD 25.5 | ▲ 0.51% |
| ACHC | Acadia Healthcare Company, Inc. | USD 34.51 | ▼ 0.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.